These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38949062)

  • 1. Poly(l-threonine-
    Park JK; Piao Z; Lee HJ; Jeong B
    Biomacromolecules; 2024 Aug; 25(8):4946-4955. PubMed ID: 38949062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo sustained release of exenatide from vesicular phospholipid gels for type II diabetes.
    Zhang Y; Zhong Y; Hu M; Xiang N; Fu Y; Gong T; Zhang Z
    Drug Dev Ind Pharm; 2016; 42(7):1042-9. PubMed ID: 26558908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained Release Strategy Designed for Lixisenatide Delivery to Synchronously Treat Diabetes and Associated Complications.
    Zhuang Y; Yang X; Li Y; Chen Y; Peng X; Yu L; Ding J
    ACS Appl Mater Interfaces; 2019 Aug; 11(33):29604-29618. PubMed ID: 31361112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo evaluation of a once-weekly formulation of an antidiabetic peptide drug exenatide in an injectable thermogel.
    Yu L; Li K; Liu X; Chen C; Bao Y; Ci T; Chen Q; Ding J
    J Pharm Sci; 2013 Nov; 102(11):4140-9. PubMed ID: 24114868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug release from a pH-sensitive multiblock co-polymer thermogel.
    Garripelli VK; Namgung R; Kim WJ; Jo S
    J Biomater Sci Polym Ed; 2012; 23(12):1505-19. PubMed ID: 21771392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation of exenatide-loaded linear poly(ethylene glycol)-brush poly(l-lysine) block copolymer: potential implications on diabetic nephropathy.
    Tong F
    Int J Nanomedicine; 2017; 12():4663-4678. PubMed ID: 28721043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biodegradable thermogels.
    Park MH; Joo MK; Choi BG; Jeong B
    Acc Chem Res; 2012 Mar; 45(3):424-33. PubMed ID: 21992012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphorylcholine-Based Zwitterionic Biocompatible Thermogel.
    Ko du Y; Patel M; Jung BK; Park JH; Jeong B
    Biomacromolecules; 2015 Dec; 16(12):3853-62. PubMed ID: 26551029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exenatide-loaded inside-porous poly(lactic-co-glycolic acid) microspheres as a long-acting drug delivery system with improved release characteristics.
    Zhai J; Ou Z; Zhong L; Wang YE; Cao LP; Guan S
    Drug Deliv; 2020 Nov; 27(1):1667-1675. PubMed ID: 33241694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liraglutide-loaded poly(lactic-co-glycolic acid) microspheres: Preparation and in vivo evaluation.
    Wu J; Williams GR; Branford-White C; Li H; Li Y; Zhu LM
    Eur J Pharm Sci; 2016 Sep; 92():28-38. PubMed ID: 27343696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sol-gel transition of nanoparticles/polymer mixtures for sustained delivery of exenatide to treat type 2 diabetes mellitus.
    Oh KS; Kim JY; Yoon BD; Lee M; Kim H; Kim M; Seo JH; Yuk SH
    Eur J Pharm Biopharm; 2014 Nov; 88(3):664-9. PubMed ID: 25152212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Acting Phospholipid Gel of Exenatide for Long-Term Therapy of Type II Diabetes.
    Hu M; Zhang Y; Xiang N; Zhong Y; Gong T; Zhang ZR; Fu Y
    Pharm Res; 2016 Jun; 33(6):1318-26. PubMed ID: 26857900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.
    Christensen M; Miossec P; Larsen BD; Werner U; Knop FK
    Expert Opin Drug Discov; 2014 Oct; 9(10):1223-51. PubMed ID: 25119443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of 1 Month Sustained-Release Microspheres Containing Liraglutide for Type 2 Diabetes Treatment.
    Gao Z; Wei Y; Ge J; Liu J; Qin Y; Gong F; Ma G
    ACS Appl Mater Interfaces; 2024 May; 16(20):25869-25878. PubMed ID: 38728411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the GLP-1 Receptor Agonist Lixisenatide on Counterregulatory Responses to Hypoglycemia in Subjects With Insulin-Treated Type 2 Diabetes.
    Farngren J; Persson M; Ahrén B
    Diabetes Care; 2016 Feb; 39(2):242-9. PubMed ID: 26537183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation and in vivo evaluation of insulin-loaded biodegradable nanoparticles prepared from diblock copolymers of PLGA and PEG.
    Haggag Y; Abdel-Wahab Y; Ojo O; Osman M; El-Gizawy S; El-Tanani M; Faheem A; McCarron P
    Int J Pharm; 2016 Feb; 499(1-2):236-246. PubMed ID: 26746800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained-release study on Exenatide loaded into mesoporous silica nanoparticles: in vitro characterization and in vivo evaluation.
    Chen C; Zheng H; Xu J; Shi X; Li F; Wang X
    Daru; 2017 Sep; 25(1):20. PubMed ID: 28870261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A long-acting formulation of a polypeptide drug exenatide in treatment of diabetes using an injectable block copolymer hydrogel.
    Li K; Yu L; Liu X; Chen C; Chen Q; Ding J
    Biomaterials; 2013 Apr; 34(11):2834-42. PubMed ID: 23352120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose lixisenatide protects against early-onset nephropathy induced in diabetic rats.
    Abdel-Latif RG; Ahmed AF; Heeba GH
    Life Sci; 2020 Dec; 263():118592. PubMed ID: 33065146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biodegradable triblock copolymer microspheres based on thermosensitive sol-gel transition.
    Kwon YM; Kim SW
    Pharm Res; 2004 Feb; 21(2):339-43. PubMed ID: 15032317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.